{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:45:19Z","timestamp":1772196319068,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.vaccine.2006.12.043","type":"journal-article","created":{"date-parts":[[2007,1,4]],"date-time":"2007-01-04T13:26:01Z","timestamp":1167917161000},"page":"2771-2777","source":"Crossref","is-referenced-by-count":32,"title":["Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine"],"prefix":"10.1016","volume":"25","author":[{"given":"S.F.","family":"Little","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.E.","family":"Ivins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.M.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.W.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.P.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.12.043_bib1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"Brey","year":"2005","journal-title":"Adv Drug Del Rev"},{"key":"10.1016\/j.vaccine.2006.12.043_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1099\/00221287-31-2-329","article-title":"The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity","volume":"31","author":"Stanley","year":"1963","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.96.4.727","article-title":"Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin","volume":"96","author":"Mahlandt","year":"1966","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/IAI.58.2.303-308.1990","article-title":"Immunization against anthrax with aromatic compound-dependent (Aro\u2212) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen","volume":"58","author":"Ivins","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/IAI.60.2.662-668.1992","article-title":"Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants","volume":"60","author":"Ivins","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib6","unstructured":"Committee to Assess the Safety and Efficacy of the Anthrax Vaccine MFA. In: Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, editors. The Anthrax Vaccine: Is It Safe? Does It Work? National Academies Press: Washington, DC; 2002."},{"key":"10.1016\/j.vaccine.2006.12.043_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US Army medical personnel","volume":"45","author":"Wasserman","year":"2003","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.vaccine.2006.12.043_bib8","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0264-410X(02)00723-5","article-title":"Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998\u20132000","volume":"21","author":"Lange","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0264-410X(02)00690-4","article-title":"Adverse medical events in British service personnel following anthrax vaccination","volume":"21","author":"Enstone","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/IAI.59.6.1961-1965.1991","article-title":"Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals","volume":"59","author":"Iacono-Connors","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib11","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/IAI.63.4.1369-1372.1995","article-title":"Protective immunity induced by Bacillus anthracis toxin-deficient strains","volume":"63","author":"Pezard","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib13","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib14","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search of correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/IAI.74.1.394-398.2006","article-title":"Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits","volume":"74","author":"Weiss","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/IAI.74.1.794-797.2006","article-title":"Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen","volume":"74","author":"Peachman","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib18","series-title":"Microbial toxins: bacterial protein toxins","first-page":"361","article-title":"Anthrax toxin","author":"Lincoln","year":"1970"},{"key":"10.1016\/j.vaccine.2006.12.043_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1099\/00221287-19-1-91","article-title":"Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo","volume":"19","author":"Harris-Smith","year":"1958","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib20","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/IAI.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/IAI.54.2.537-542.1986","article-title":"Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis","volume":"54","author":"Ivins","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/cjm-45-1-1","article-title":"Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis","volume":"45","author":"Worsham","year":"1999","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/AEM.64.3.982-991.1998","article-title":"Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis","volume":"64","author":"Farchaus","year":"1998","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib24","first-page":"103","article-title":"Production and purification of anthrax toxin","volume":"vol. 165","author":"Leppla","year":"1988"},{"key":"10.1016\/j.vaccine.2006.12.043_bib25","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunty in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib26","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(84)90003-3","article-title":"Anthrax: the disease in relation to vaccines","volume":"2","author":"Hambleton","year":"1984","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib28","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","article-title":"Development of an in vitro-based potency assay for anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","author":"Little","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib31","first-page":"125","article-title":"Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys","volume":"87","author":"Ivins","year":"1996","journal-title":"Salisbury Med Bull"},{"key":"10.1016\/j.vaccine.2006.12.043_bib32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0264-410X(02)00556-X","article-title":"Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production","volume":"21","author":"Iyer","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00189414","article-title":"Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"177","author":"Turnbull","year":"1988","journal-title":"Med Microbiol Immunol Berl"},{"key":"10.1016\/j.vaccine.2006.12.043_bib34","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2004.10.014","article-title":"Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants","volume":"23","author":"Berthold","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib35","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib36","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib37","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.vaccine.2003.11.064","article-title":"Pluronic\u00ae F127-based systemic vaccine delivery systems","volume":"22","author":"Coeshott","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vaccine.2004.05.029","article-title":"Anthrax capsule vaccine protects against experimental infection","volume":"23","author":"Chabot","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.vaccine.2005.08.056","article-title":"N-fragment of edema factor as a candidate antigen for immunization against anthrax","volume":"24","author":"Zeng","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib40","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4049\/jimmunol.176.3.1776","article-title":"Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens","volume":"176","author":"Duverger","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.12.043_bib41","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.12.043_bib42","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.12.043_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/430708","article-title":"A phase I study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers","volume":"41","author":"Subramanian","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2006.12.043_bib45","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1128\/IAI.73.12.8362-8368.2005","article-title":"Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region","volume":"73","author":"Mabry","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib47","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","article-title":"Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax","volume":"74","author":"Peterson","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib48","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1016\/j.vaccine.2006.04.065","article-title":"Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization","volume":"24","author":"Herrmann","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.12.043_bib49","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/IAI.00712-06","article-title":"Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity","volume":"74","author":"Vitale","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.12.043_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/IAI.70.2.661-664.2002","article-title":"Anthrax spores make an essential contribution to vaccine efficacy","volume":"70","author":"Brossier","year":"2002","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06013831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06013831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:57:07Z","timestamp":1683705427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06013831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":50,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0264410X06013831"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.12.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}